JP2005509642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509642A5 JP2005509642A5 JP2003538181A JP2003538181A JP2005509642A5 JP 2005509642 A5 JP2005509642 A5 JP 2005509642A5 JP 2003538181 A JP2003538181 A JP 2003538181A JP 2003538181 A JP2003538181 A JP 2003538181A JP 2005509642 A5 JP2005509642 A5 JP 2005509642A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- solvate
- physiologically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- -1 heteroaryl compound Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- GBTODAKMABNGIJ-VWLOTQADSA-N 3-[4-[6-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexoxy]butyl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CCCCOCCCCCCNC[C@H](O)C=2C=C(CO)C(O)=CC=2)=C1 GBTODAKMABNGIJ-VWLOTQADSA-N 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002596 lactones Chemical group 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 0 N*(CCCO1)C1=O Chemical compound N*(CCCO1)C1=O 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N O=C1OCC=C1 Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0125259.2A GB0125259D0 (en) | 2001-10-20 | 2001-10-20 | Novel compounds |
| PCT/EP2002/011634 WO2003035668A2 (en) | 2001-10-20 | 2002-10-17 | Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005509642A JP2005509642A (ja) | 2005-04-14 |
| JP2005509642A5 true JP2005509642A5 (enExample) | 2006-01-05 |
| JP4495456B2 JP4495456B2 (ja) | 2010-07-07 |
Family
ID=9924247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003538181A Expired - Lifetime JP4495456B2 (ja) | 2001-10-20 | 2002-10-17 | 新規の抗炎症性アンドロスタン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7405206B2 (enExample) |
| EP (1) | EP1444248B1 (enExample) |
| JP (1) | JP4495456B2 (enExample) |
| AT (1) | ATE393771T1 (enExample) |
| AU (1) | AU2002350561A1 (enExample) |
| DE (1) | DE60226334T2 (enExample) |
| ES (1) | ES2304457T3 (enExample) |
| GB (1) | GB0125259D0 (enExample) |
| WO (1) | WO2003035668A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| EP2067784A3 (en) | 2000-08-05 | 2012-08-22 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| WO2002088167A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| US7910708B2 (en) | 2005-10-21 | 2011-03-22 | Novartis Ag | Anti-IL13 human antibodies |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| AR059216A1 (es) * | 2006-01-27 | 2008-03-19 | Sun Pharmaceutical Ind Ltd | 11b-hidroxiandrosta-4-eno-3-onas |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| ATE549337T1 (de) | 2006-04-21 | 2012-03-15 | Novartis Ag | Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘 |
| RS51644B (sr) | 2007-01-10 | 2011-10-31 | Irm Llc. | Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze |
| KR20100005730A (ko) | 2007-05-07 | 2010-01-15 | 노파르티스 아게 | 유기 화합물 |
| EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| SI2379507T1 (sl) | 2008-12-30 | 2014-02-28 | Pulmagen Therapeutics (Inflammation) Limited | Spojine sulfonamida za zdravljenje respiratornih motenj |
| PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
| EP2443134A2 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | NOVEL [3,2-c]HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| MY162604A (en) | 2009-08-17 | 2017-06-30 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物 |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| AU2012220572A1 (en) | 2011-02-25 | 2013-08-29 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| CN110507654A (zh) | 2012-04-03 | 2019-11-29 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| US10155001B2 (en) | 2013-06-14 | 2018-12-18 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | RAC1 inhibitors for inducing bronchodilation |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
| PL3134395T3 (pl) | 2014-04-24 | 2018-07-31 | Novartis Ag | Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| KR20170036037A (ko) | 2014-07-31 | 2017-03-31 | 노파르티스 아게 | 조합 요법 |
| EP3980121A1 (en) | 2019-06-10 | 2022-04-13 | Novartis AG | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| PH12022550468A1 (en) | 2019-08-28 | 2023-03-06 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3828080A (en) * | 1972-01-20 | 1974-08-06 | Glaxo Lab Ltd | Androstane-17beta-carboxylic acids and processes for the preparation thereof |
| GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
| CY1359A (en) * | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| SK89198A3 (en) * | 1995-12-29 | 1999-03-12 | Glaxo Group Ltd | Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives |
| GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| EP2067784A3 (en) * | 2000-08-05 | 2012-08-22 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6858593B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6777400B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| EP1480996A1 (en) * | 2002-02-04 | 2004-12-01 | Glaxo Group Limited | Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
| US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
-
2001
- 2001-10-20 GB GBGB0125259.2A patent/GB0125259D0/en not_active Ceased
-
2002
- 2002-10-17 ES ES02785235T patent/ES2304457T3/es not_active Expired - Lifetime
- 2002-10-17 AU AU2002350561A patent/AU2002350561A1/en not_active Abandoned
- 2002-10-17 EP EP02785235A patent/EP1444248B1/en not_active Expired - Lifetime
- 2002-10-17 JP JP2003538181A patent/JP4495456B2/ja not_active Expired - Lifetime
- 2002-10-17 WO PCT/EP2002/011634 patent/WO2003035668A2/en not_active Ceased
- 2002-10-17 DE DE60226334T patent/DE60226334T2/de not_active Expired - Lifetime
- 2002-10-17 US US10/492,813 patent/US7405206B2/en not_active Expired - Lifetime
- 2002-10-17 AT AT02785235T patent/ATE393771T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3980400B1 (en) | Peptidomimetics for the treatment of coronavirus and picornavirus infections | |
| JP6964096B2 (ja) | ３−オキソ−２，６−ジフェニル−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| EP3795566B1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| EP2595620A2 (fr) | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide | |
| JPH06211870A (ja) | ラパマイシンのカルバメート | |
| JP2007505931A5 (enExample) | ||
| JP2019112307A (ja) | 置換ジヒドロピロロピラゾール化合物および他の乾癬治療薬が組み合わせて投与される医薬組成物 | |
| US20060148730A1 (en) | Method of treating tuberculosis | |
| JP2026016715A (ja) | 狂犬病治療のための環状アミド化合物およびその方法 | |
| CN1343216A (zh) | 红霉素衍生物 | |
| JP7835403B2 (ja) | イタコネートおよびメチルイタコネートの新規プロドラッグ | |
| EP3166955B1 (en) | Hamamelitannin analogues and uses thereof | |
| JP3378239B2 (ja) | ベンゾフロキサン誘導体及びそれを含有する心臓血管性疾患治療剤 | |
| JP2013522374A (ja) | 創傷の予防及び治療のための組成物及び方法 | |
| EP2175850A1 (en) | Methods for treating anxiety | |
| CA2451238A1 (en) | Cyclic diamine compound with 5 membered ring groups | |
| CN115916345B (zh) | 吡咯并吡啶衍生物及其用途 | |
| JP2022536043A5 (enExample) | ||
| WO2004028526A1 (ja) | ベンズアミド誘導体を有効成分とするリウマチ治療剤 | |
| WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| WO2003045953A1 (en) | Crystals of taxane derivative and process for their production | |
| CN117126153A (zh) | 一种新冠病毒抑制剂，其制备方法和其药物组合物与用途 | |
| CN107056819B (zh) | 一种预防和治疗心肌缺血的药物及其制备方法 | |
| JP2008520686A (ja) | 新規な抗菌化合物の使用 | |
| CN100422161C (zh) | 羟基吗啉酮衍生物及其医药用途 |